37 results
8-K
EX-99.1
MLYS
Mineralys Therapeutics, Inc.
13 Aug 24
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
4:07pm
and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company’s expectation … that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Company’s expectation
8-K
MLYS
Mineralys Therapeutics, Inc.
10 Jun 24
Other Events
4:02pm
, but are not limited to, statements regarding: the Company’s plan to revise the primary endpoint for the Advance-HTN trial; the potential therapeutic benefits … of lorundrostat; the Company’s expectation that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits
8-K
EX-99.1
MLYS
Mineralys Therapeutics, Inc.
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company’s expectation that aldosterone synthase inhibitors with an SGLT2 … inhibitor may provide additive clinical benefits to patients; the Company’s expectation that the Advance-HTN and the planned Phase 3 clinical trial
424B5
631l65hyw4y5fk rsmr
11 Apr 24
Prospectus supplement for primary offering
4:35pm
DEF 14A
p38agxnvhy hv
9 Apr 24
Definitive proxy
7:15am
8-K
EX-99.1
l17u0 d2lt432erflh
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
S-3
EX-4.3
g3m7fr9d6b9d0 qdx
21 Mar 24
Shelf registration
7:30am
S-3
EX-1.2
oragl721pxau 2bjk
21 Mar 24
Shelf registration
7:30am
S-3
spkq azj5xd
21 Mar 24
Shelf registration
7:30am
8-K
EX-10.1
uxna6x7
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
EX-99
oc3fuazvkf6 2f
4 Jan 24
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
4:10pm
8-K
EX-99.1
l6mrhf tjn027ug122c
22 Dec 23
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
9:04am
8-K
som0l3
13 Nov 23
Regulation FD Disclosure
8:20am
8-K
EX-99.1
9imf wpq58gs2
13 Nov 23
Regulation FD Disclosure
8:20am